9:30 AM
 | 
Apr 14, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ALX148: Ph I AT148001 started

Alexo began the 2-part, open-label, dose-escalation, U.S. Phase I AT148001 trial to evaluate ALX148 in about 110 patients. Part 1 will evaluate ascending doses of...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >